title: Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
abstract: We report two cases of multicentric Castleman's disease (MCD) whose serum hepcidin levels were rapidly down-regulated by administration of tocilizumab, an anti- interleukin 6 (IL-6) receptor antibody. Our results indicate that IL-6-induced hepcidin over-production may be involved in the pathophysiology of microcytic anemia commonly observed in this disease.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawabata
authors.forename: Naohisa
authors.initials: N
authors.lastname: Tomosugi
authors.forename: Junya
authors.initials: J
authors.lastname: Kanda
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Yoshizaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Uchiyama
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D023181:Antimicrobial Cationic Peptides / Q000097:blood / Q000187:drug effects*; D005871:Castleman Disease / Q000188:drug therapy*; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D064451:Hepcidins; D006801:Humans; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D023181:Antimicrobial Cationic Peptides; C578702:HAMP protein, human; D064451:Hepcidins; D019947:Receptors, Interleukin-6; C502936:tocilizumab